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1. Introduction
Ovarian cancer is one of the 
most fatal female reproductive sys-
tem cancers [1]. Based on data pro-
vided by the WHO, 225,500 cases 
of ovarian cancer are diagnosed 
worldwide each year and 140,200 
deaths are reported. Among the 
female population, according to 
world statistics, ovarian cancer 
ranks 7th in the structure of mor-
bidity and 8th in the structure of 
mortality [2, 3]. According to the 
Ukraine National Cancer Regis-
try (2019), ovarian cancer occupies 
the 6th position both in the mor-
bidity and mortality structure of 
women population [4].
Epithelial malignant neo-
plasms of the ovaries account 
for 40 % of all oncopathology [5], 
with SOC being the leading his-
totype and covering 68–71 % of 
epithelial neoplasms [6]. There 
are 2 types of SOC, which differ 
in origin, biological behavior and 
prognosis for patients. Type I is 
represented by serous carcinoma 
of low malignancy (LGSC), and 
type II – serous carcinoma of 
high malignancy (HGSC). [7] Al-
though LGSC accounts for only 
5 % of all SOCs, and the leading 
role is played by HGSC [8], the 
study of molecular genetic and 
biological features of LGSC is ex-
tremely important for the ability 
to predict tumor behavior and 
selection of targeted therapy.
In recent years, much atten-
tion has been paid to the study of 
CSCS population and their role 
in the cancer progression. Nu-
merous studies have shown that 
although CSCS account for only 
a few percent of tumor mass, they 
are one of the leading predictors 
of chemoresistance, recurrence 
and metastasis of SOC [9, 10]. 
The population of CSCS in ovar-
ian tumor tissue is determined 
by a number of surfaces IHC-markers (CD44, CD117, CD133) 
and intracellular markers (Nanog, Oct4 and Sox2) [11, 12]. The 
origin of CSCS is also debatable: according to some data, normal 
stem cells can become a source of the CSCS pool, according to 
other data, stem tumor cells are transformed from carcinoma 
cells. In addition, many studies have focused on the plasticity 
properties of CSCS and their relationship to EMT. According to 
some researchers, carcinoma phenotype changes dynamically 
from epithelial to mesenchymal depending on disease stage and 
presence of metastases, and it correlates with increased levels of 
CSCS expression and worsening prognosis [13].
The aim of our research was studying of expression surface 
CSCS markers CD44 and CD117 in LGSC with subsequent re-
currence and without it, as well 
as the relationship between the 
expression of CSCS and EMT 
markers to identify possible pre-
dictors of recurrence in patients.
2. Materials and methods
The material for our research 
were case histories, paraffin blocks 
and slides of 43 patients with LGSC 
who underwent surgery in the 
amount of bilateral salpingooo-
phorectomy and hysterectomy 
with resection or extirpation of the 
large omentum with subsequent 
adjuvant chemotherapy and previ-
ous neoadjuvant chemotherapy in 
cases of advanced stages. Surgical 
interventions were performed at 
the Institute of Medical Radiology 
and Oncology. S. P. Grigoriev, Re-
gional Clinical Oncology Center 
(Kharkov) in the period from 2013 
to 2018. The prevalence of the tu-
mor process was assessed accord-
ing to the FIGO classification. The 
study included LGSC with disease 
stage I–IV: 30 cancers without re-
currence over the next 24 months 
(main group) and 13 cancers with 
recurrence (comparison group) in 
the specified time interval. The 
age of the patients varied from 28 
to 56 years (average age 42.7±0.91). 
Histological type of tumors was 
determined during examination 
of slieds stained with hematoxy-
lin-eosin. From each clinical case, 
1 paraffin block was selected for 
IHC-study.
All patients signed informed 
consent for the using their infor-
mation from case histories, paraf-
fin blocks and slides in our study.
For the IHC study, the ma-
terial was fixed with 10 % neu-
tral formalin for 24 h, embedded 
in paraffin, prepared 4 μm thick 
sections, which were applied to 
highly adhesive Super Frost slides 
and dried at 37 °C for 18 hours. 
Unmasking heat treatment was performed by boiling the sections 
in citrate buffer (pH 6.0). UltraVision Quanto Detection Systems 
HRP Polymer (Thermo scientific) was used to visualize primary 
antibodies. DAB (diaminobenzidine) was used as the chromogen.
Primary monoclonal antibodies (MCAT) from DAKO 
(Denmark), TermoScientific (Germany) and Diagnostic BioSys-
tems (USA) were used. The expression of the following markers 
was studied: E-cadherin (EP7004, Termo Scientific), Vimentin 
(Diagnostic BioSystems), CD117 (Diagnostic BioSystems), CD44 
(Clone: 156-3C11, Dako Cytomation).
To assess the intensity of IHC mark used a semi-quantitative 
scale 0–3 +: 0 – no expression, + – weak, ++ – moderate, +++ – 
a pronounced reaction. To quantify the IHC mark, E-cadherin 
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Abstract: Ovarian cancer remains one of the most fatal 
pathologies among women around the world due to late 
diagnosis on the advanced stages of the tumor process. Se-
rous ovarian carcinomas (SOC) often recur, which worsens 
the prognosis for patients’ recovery and survival. The iden-
tification of prognostic clinical and morphological factors 
that predict the appearance of recurrence remains an urgent 
problem.
The aim of the research was studying relationships between 
the phenomenon of epithelial-mesenchymal transforma-
tion (EMT) and the expression of surface cancer stem cells 
(CSCS) markers to identify recurrence predictors among 
women with low grade serous ovarian carcinomas (LGSC).
The material were paraffin blocks and slides of 43 patients 
with LGSC I-IV FIGO stage. The study included 30 cancers 
without recurrence and 13 tumors with it within 24 months. 
The expression of E-cadherin, Vimentin, CD44 and CD117 
was studied using immunohistochemical (IHC) method.
Results. Development of recurrence is typical for wom-
en with stage III–IV (p=0.01), the expression of Vimentin 
at level 51–100 % (p=0.001) and E-cadherin at 10–50 % 
(p=0.04). CD44 was expressed in 51.16 % of tumors and 
level didn`t depend on age, recurrence, but depended on 
disease stage (p=0.001). Recurrent LGSCs are characterized 
by the expression of CD117>10 % (p=0.0001), its direct 
correlation with the stage (p=0.0001) and the recurrence 
(p=0.0001). A direct relationship was found between the 
CD117 and Vimentin expression.
Conclusions. Prognostic markers of recurrence should 
be considered stage III-IV, levels of Vimentin 51–100 %, 
E-cadherin 10-50 % and CD117>10 %. A correlation be-
tween CD117 and Vimentin expression indicates the com-
monality of EMT and CSCS in progression and recur. CD44 
has no independent prognostic role.
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and Vimentin took into account the percentage of staining: 
0 – no staining, <10 % of nuclei – weak, 10–50 % – moderate, 
51–100 % – high expression. To assess the immunohistochemical 
label CD117 and CD44, the level of staining >10 % was considered 
high, ≤10 % – low, 0 – no staining. Only cells with moderate (++) 
and high (+++) color intensity were taken into account.
Statistical analysis was performed using the Mann-Whitney 
test to assess differences between two groups on the level of trait. 
Spearman’s rank correlation method was used to assess the cor-
relation. Pearson’s Yets-corrected test was used to assess differ-
ences between the study groups. The level of significance≤0.05 
was considered significant.
3. Results
Analysis of general clinical characteristics showed that age 
of patients in the main group ranged from 35 to 51 years (medi-
an=42.97±0.81 years), and in the comparison group age fluctua-
tions ranged from 28 to 56 years (median=42.08±2.43 years). Age 
differences of the compared groups are statistically insignificant 
(Uemp=191 at Ucrit=132). Menopause occurred in 23.08 % (3/13) of 
patients from the group of recurrent LGSCs, in the group of LGSCs 
without recurrence menopause was recorded in 13.33 % (4/30) cas-
es. For LGSCs without recurrence are typical initial (I–II) stages 
of the disease with no terminal (IV) stage, while recurrent LGSCs 
are characterized by disease stage III-IV with no cases diagnosed 
in stage I (χ²=20.95, p=0.0051) and a significant decreasing of cases 
diagnosed in stage II (χ²=14.37, p=0.0059) (Table 1).
Table 1
Distribution of tumors (n=43) depending on the stage of the 
disease according to FIGO
FIGO 
stage
Main group  
n=30 (%)
Comparison group  
n=13 (%)
I 6 (20)* 0*
II 20 (66,67)** 1 (7,69)
III 4 (13,33)*** 10 (76,92)
IV 0 2 (15,38)
Note: * – insignificant difference between I and II stages (χ²=0.46, p=0.5), 
III and IV stages (χ²=0, p=1); ** – significant difference between II and 
III stages (χ²=14.37, p=0.0002); *** – significant difference between I–II 
and III–IV stages of the disease (χ²=20.95, p=0.0001)
The study did not show association between the patients̀  
age and disease recurrence in the control group (r=0.402, 
p=0.0049) and the study (r=0.159, p=0.07). At the same time 
Fig. 1 shows a direct strong correlation between FIGO stage and 
development of recurrence of SOC (r=0.69, p=0.00039).
Analyzing the expression of EMT markers (Table 2), it was 
found that both carcinoma groups are characterized by Vimentin 
expression at ≥10 %. The control group is typical for a moderate 
expression level (median 35.27 %±1.93) with increasing number of 
cases of high level of marker expression in the comparison group 
(χ²=16.21, p=0.006), where the average level expression reached 
61.15 %±3.95. Analyzing the expression of Vimentin depending on 
stage, it was noticed that in both LGSC groups moderate expres-
sion of Vimentin is typical for I–II stage of the disease (χ²=15.13, 
p=0.0001), while for III–IV is typical expression level>50 %.
Regarding the expression of E-cadherin, statistically signifi-
cant differences between moderate and high levels of expression 
in tumors with recurrence and without were not detected (χ²=2.6, 
p=0.1), while for both groups the expression level was ≥10 %. In 
the control group, the expression level acquired values from 26 % 
to 68 % (median=30.15 %±2.78), and in the comparison group the 
values ranged from 11 % to 47 % (median=46.57±1.77 %). Interest-
ingly, despite the lack of differences in the levels of E-cadherin ex-
pression, in tumors with recurrence there is a tend to decrease the 
level of IHC-mark (Uemp=43 at Ucrit=132). It was found that LGSC 
III-IV stages are characterized by a moderate level of E-cadherin 
expression (χ²=4.03, p=0.04) with a decrease in the number of cases 
of high marker expression in the control group and the absence of 
such cases in recurrence LGSC. There is an inverse relationship 
between E-cadherin expression and FIGO stage (r=0.32, p=0.034) 
and development of recurrence (r=0.62, p=0.00031) (Fig. 2).
Table 2
Distribution of tumors (n=43) depending on the level of 
expression of IHC markers of EMT and the disease stage by FIGO
Expression level Main group n=30 Comparison group n=13
E-cadherin I II III IV I II III IV
0 % – – – – – – – –
<10 % – – – – – – – –
10–50 % – 18 4 – – 1 10 2
51–100 % 6 2 – – – – –
Vimentin
0 % – – – – – – – –
<10 % – – – – – – – –
10–50 % 6 19 2 – – – 3 –
51–100 % – 1 2 – – 1 7 2
Considering the expression of surface CSCS markers (Ta-
ble 3), it was found that CD44 +– status had 51.16 % (22/43) of all 
tumors: in the comparison group CD44 + tumors were observed 
in 69.23 % (9/13) cases, and in the control group in 43.33 % 
(13/30) of the studied tumors. In LGSC with recurrence, the lev-
el of CD44 expression ranged from 8 % to 14 % with an average 
value of 7.46 %±1.49, in LGSC without reoccur, the IHC-index 
varied between 6–14 % with a median of 4.13 %±0.91. No statis-
tically significant differences between marker expression levels 
in the study groups were found (χ²=2.74, p=0.098).
The dependence of marker expression on age (rs=0.128, 
p=0.41) and the presence of recurrence (rs=0.29, p=0.057) was 
not detected, while the dependence of CD44 expression on the 
FIGO stage was found (rs=0.483, p=0.001) (Fig. 3).
Regarding the CD117 expression, it should be noted that 
39.53 % (17/43) of tumors had CD117-negative status: 7.69 % 
(1/13) belonged to the comparison group and 53.33 % (16/30) to 




















y = -0,657  +  0,421  x 
n = 43
r = 0,69; P < 0,001
Fig. 1. Graphical representation of the relationship between 
FIGO stage and LGSC recurrence
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expression at the level of 0–10 % with a median of 5.37 %±1.19 
and a range of values from 6 % to 19 % with a statistically 
significant (χ²=14.81, p=0.00043) increase in the number of 
cases of high expression level in comparison group (median 
13.85 %±1.55) and the increase of expression level in the group 
of recurrent LGSC (Uemp=62 at Ukrit=132). For stage III–IV there 
is a tend to increase number of cases with expression> 10 %, 
while for the initial stages more typical expression at the level of 
0–10 % (χ²=26.68, p=0.00067). A strong correlation was found 
between the CD117 expression and stage of the disease (rs=0.84, 
р=0.0002), the presence of recurrence (rs=0.54, р=0.00033). At 
the same time, there is no relationship between CD117 + tumor 
status and patient’s age (rs=0.183 p=0.24) (Fig. 4). 
Coexpression of markers, studied in our study, revealed a direct 
correlation between CD117 and CD44 expression (rs=0.73, p=0.001), 
as well as between Vimentin expression (rs=0.64, p=0.0006), the 
inverse correlation between E-cadherin and Vimentin expression 
(rs=–0.32, p=0.038). Coexpression of CD44 and E-cadherin shows 
no dependence (rs=0.08, p=0.615). Results are displayed in Fig. 5.
Table 3
Distribution of tumors (n=43) depending on the level of CSCS 
markers and the stage of the disease according to FIGO
Expression level Main group n=30 Comparison group n=13
CD44 I II III IV I II III IV
0 % 3 14 – – – – 4
≤10 % 2 4 2 – – 1 2 –
>10 % 1 2 2 – – 4 2
CD117
0 % 6 10 – – – 1 – –
≤10 % – 7 – – – – – –
>10 % – 3 4 – – – 10 2
















y = 3,118 + -0,0202  x
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y = 1,275 + -0,0234  x
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y = 1,910  +  0,0718  x 
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y = 0,170  +  0,0257  x 
n = 43
r = 0,29; P = 0,057
Fig. 3. Graphic representation of the relationship between CD44 expression and disease stage (left) and relapse (right)
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y = 0,0311  +  0,0342  x 
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Clinical data of our study show that recurrence of LGSC 
occur in patients with stage III–IV disease by FIGO (p=0.0051) 
and were not detected in stage I, although according to the lit-
erature LGSC have an indolent course, less often diagnosed on 
advanced stages and have more favourable prognosis [7, 14]. The 
relationship is confirmed by a direct correlation between disease 
stage and reoccur (p=0.00039). The presence of large number of 
patients with stage III–IV in the study, in our view, is due to un-
timely treatment of patients, because in the early stages ovarian 
tumors are mostly asymptomatic. An additional adverse factor 
for early detection of SOC is the low consciousness of women, 
who neglect preventive gynecological examinations. Detection 
of recur in the neglected stages is due to the prevalence of the 
tumor process, which is less susceptible to cytoreduction and 
treatment. The age of onset of LGSCs in two comparable groups 
didǹ t differ: sick patients aged 42 years, which coincides with 
data of other studies and the average age of onset of LGSCs ac-
cording to the WHO (43 years) [8, 14, 15].
Results of IHC studies show that recurrent LGSCs (p=0.006) 
and tumors detected in stages III–IV (p=0.0001) are character-
ized by the expression level of Vimentin 51–100 %. The expres-
sion of E-cadherin in stages III–IV tends to remain at 10–50 % 
(p=0.04) in both groups with a relative decrease in all stages in 
the recurrent LGSCs. It was also observed that with a decrease 
of E-cadherin expression, the FIGO stage worsens (p=0.034) 
and the probability of recurrence increases (p=0.00031), with a 
decrease of marker expression decreases the adhesion properties 
of tumors and increases their ability to invade and metastasize, 
which will indicate a deterioration of the stage by FIGO. At the 
same time, in our study, all tumors showed the phenomenon of 
EMT with the acquisition of a pronounced mesenchymal phe-
notype and loss of epithelial phenotype in tumors with disease 
stage III–IV (p=0.038). The obtained data do not contradict the 
literature about the key role of EMT in tumor metastasis and 
progression [16].
CD44 expression was observed in 51.16 % of all tumors, and 
level of expression in the study groups did not change signifi-
cantly (p=0.098). CD44 +-status didǹ t depend on age (p=0.41) 
and recurrence (p=0.057), but there was a direct correlation with 
the FIGO stage (p=0.001). Similar data were obtained in other 
studies [17, 18], at the same time in the work of Sillanpää S. et 
al. there is controversy about a direct correlation between CD44 
expression and highly differentiated tumors detected in the ear-
ly stages and long-term recurrence-free survival of patients [19]. 
CD117 + – status had 60.47 % of all tumors, recurrent LGSCs 
were characterized by an expression level>10 % (p=0.00067) 
with increasing values of the IHC mark. The frequency of ex-
pression according to the literature reaches 40 % [9], and the 
difference with our data can be explained by the characteris-
tics of a particular sample. For the initial stages of the disease 
according to FIGO, the typical level of CD117 expression was 
0–10 % (p=0.00043) with an increase of cases number of high 
expression in stages III-IV. As for CD44, the CD117 marker 
did not show a dependence on the age of patients (p=0.24), but 
there is a strong correlation between the FIGO stage (р=0.0002) 
and tumor recurrence (p=0.00033), which supported by data 
from another study [9]. At the same time, it was found that the 
level of CD44 expression increases with increasing expression 
level of CD117, which confirms the phenotype of ovarian CSCS, 
because to verify this pool itself, the coexpression of these two 
markers is always studied [9]. There is also a direct correlation 
between the expression level of CD117 and Vimentin, which, 
in our opinion, indicates the commonality of EMT and CSCS 
in progression and recurrence of ovarian cancer. Coexpression 
of CD44 and E-cadherin was not found in our study (p=0.615), 
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which is somewhat unexpected, because CD44 is a transmem-
brane glycoprotein, which, like E-cadherin, is involved in inter-
cellular adhesion. The heterogeneity of the expression of the two 
markers can be explained by the complexity of the mechanisms 
of intercellular adhesion and the peculiarities of the microenvi-
ronment of tumor cells, because CD44 has many functions and 
can function as a signalling transmitter, which is also involved 
in invasion and migration of tumor cells [20].
Study limitations. The study analyzed 43 carcinomas, 
which is a sufficient reference sample. However, it should be 
borne in mind that obtained results are specific only for LGSC 
and may lose their relevance and informativeness when applied 
to high-grade serous ovarian carcinomas due to the different 
biological origins of two groups of tumors.
Prospects for further research. Given the relevance and 
prospects of studying the role of CSCS in tumor progression, 
metastasis and recurrence, it is interesting to study the relation-
ship of other CSCS markers (Sox2, CD133, Oct4) with the onset 
of recurrence of SOC, as well as their relationship with EMT.
6. Conclusions
Based on the data of our study, in the risk group for recur-
rence of LGSC are women with stage III-IV disease according 
to FIGO, and the likelihood of recurrence increases with in-
creasing stage. Recurrent carcinomas are also characterized by 
EMT phenomenon with expression level of Vimentin 51–100 % 
and expression of E-cadherin at level of ≤50 %. In our study, we 
did not find a prognostic role of the CD44 marker as a predictor 
of recurrence or worsening of the SOC stage, it should be used, 
in our opinion, as an additional marker that identifies pool of 
ovarian CSCS. A prognostic role in the deterioration of the stage 
and appearance of recurrence was found for CD117, for recur-
rent LGSC typical expression level>10 %. The direct correlation 
between CD117 expression and Vimentin proves the common 
role of EMT process and CSCS in recur and progression of 
LGSC.
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